search
Back to results

The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects (THAM)

Primary Purpose

Nephropathy

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
hypertonic saline
Sponsored by
Regional Hospital Holstebro
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Nephropathy focused on measuring Nephrology, sodium-channels, water-channels, BCM, central blood pressure

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy males and females
  • age 18-45
  • BMI range 18,5-30,0 kg/m2

Exclusion Criteria:

  • hypertension (i.e. ambulatory BP > 130 mmHg systolic or/and > 80 mmHg diastolic)
  • history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic
  • disease.
  • alcohol abuse
  • drug abuse
  • smoking
  • pregnancy or nursing
  • blood donation within a month prior to examination
  • medical treatment apart from oral contraception abnormal blood samples, -ECG and -urine dipstick, drug abuse, alcohol abuse, pregnancy, medication

Sites / Locations

  • Medical Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

thiazide, diuretic

amiloride, diuretic

calcium

Arm Description

1.25 mg thiazide twice daily for 5 days

5 mg of amiloride twice daily

placebo twice daily for 5 days

Outcomes

Primary Outcome Measures

urinary biomarkers
Urinary excretion of epithelial sodium channels (ENaC), Sodium-potassium-2chloride transporters (NKCC2) and aquaporin2 channels (AQP2) before, during and after fluid infusion

Secondary Outcome Measures

vaso active hormones
plasma concentrations of: renin, Angiotensin II, aldosterone, Vasopressin, ANP and BNP
central blood pressure
measured by applanation-tonometry
intracellular (ICV)- and extracellular volume (ECV)
change in ICV and EVC from baseline and after intervention measured in liters by body composition monitor (BCM)

Full Information

First Posted
June 13, 2012
Last Updated
March 1, 2014
Sponsor
Regional Hospital Holstebro
search

1. Study Identification

Unique Protocol Identification Number
NCT01635231
Brief Title
The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects
Acronym
THAM
Official Title
Effect of Thiazide, Amiloride and Hypertonic Saline on Sodium- and Water Channel Activity in the Nephron in Healthy Subjects Estimated by Urinary Biomarkers
Study Type
Interventional

2. Study Status

Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Regional Hospital Holstebro

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) reflects the activity of the sodium- and water channels in the human kidney. Changes in the sodium-and water channel activity can be induced by blocking the sodium channels with diuretics in healthy subjects
Detailed Description
Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) reflects the kidneys transport of sodium and water in the nephron. Changes in the sodium-and water channel activity is induced by blocking the NCC channels with thiazide and ENaC channels with amiloride and by intervention with hypertonic NaCl The changes in sodium-and water channels are followed by changes in extracellular and intracellular fluids, central bloodpressure and the plasma concentration of vasoactive hormones. The purpose of this study is to investigate the changes in urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2), extra- and intracellular fluid compartments, central bloodpressure and the plasma concentration of Vasoactive hormones in healthy subjects under a) treatment with Amiloride and Thiazide at baseline and b) after and acute infusion with hypertonic saline. Subjects will be examined on three examination days. Four days prior to the examination days the subjects will consume a standard diet based on amount of sodium and calories and randomized to treatment with either thiazide, amiloride or placebo twice daily for 5 days. On the examination days the subjects receive an infusion with hypertonic saline. Renal function is measured by renal clearance of 51Cr-EDTA. Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) will be measured to evaluate the activity of water- and sodium channels in the nephron, changes in fluid compartments are measured by body composition monitor. Central blood pressure is measured by sphygmocor.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nephropathy
Keywords
Nephrology, sodium-channels, water-channels, BCM, central blood pressure

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
thiazide, diuretic
Arm Type
Active Comparator
Arm Description
1.25 mg thiazide twice daily for 5 days
Arm Title
amiloride, diuretic
Arm Type
Active Comparator
Arm Description
5 mg of amiloride twice daily
Arm Title
calcium
Arm Type
Placebo Comparator
Arm Description
placebo twice daily for 5 days
Intervention Type
Other
Intervention Name(s)
hypertonic saline
Other Intervention Name(s)
NaCl 3.0 %
Intervention Description
hypertonic saline 3.0% 7 ml/kg
Primary Outcome Measure Information:
Title
urinary biomarkers
Description
Urinary excretion of epithelial sodium channels (ENaC), Sodium-potassium-2chloride transporters (NKCC2) and aquaporin2 channels (AQP2) before, during and after fluid infusion
Time Frame
baseline, 0 hours and 1.5 hours after intervention
Secondary Outcome Measure Information:
Title
vaso active hormones
Description
plasma concentrations of: renin, Angiotensin II, aldosterone, Vasopressin, ANP and BNP
Time Frame
baseline, 0 hours and 1.5 hours after intervention
Title
central blood pressure
Description
measured by applanation-tonometry
Time Frame
baseline, 0 hours and 1.5 hours after intervention
Title
intracellular (ICV)- and extracellular volume (ECV)
Description
change in ICV and EVC from baseline and after intervention measured in liters by body composition monitor (BCM)
Time Frame
baseline, 0 hours and 1.5 hours after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: healthy males and females age 18-45 BMI range 18,5-30,0 kg/m2 Exclusion Criteria: hypertension (i.e. ambulatory BP > 130 mmHg systolic or/and > 80 mmHg diastolic) history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic disease. alcohol abuse drug abuse smoking pregnancy or nursing blood donation within a month prior to examination medical treatment apart from oral contraception abnormal blood samples, -ECG and -urine dipstick, drug abuse, alcohol abuse, pregnancy, medication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erling B Pedersen, MD, DMSc
Organizational Affiliation
Medical Research, Holstebro
Official's Role
Study Director
Facility Information:
Facility Name
Medical Research
City
Holstebro
ZIP/Postal Code
7500
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects

We'll reach out to this number within 24 hrs